Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130715 · ClinicalTrials.gov registry record · NA
Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
A NA study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- NA
- Development phase
NCT00130715 is a NA study that has completed, run by Genzyme, a Sanofi Company.
The verdict
NCT00130715, a NA study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic abscess within 6 months postoperatively.
Interventions
- DEVICE Seprafilm Bioresorbable Membrane
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2003-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130715
The ClinicalTrials.gov registry entry for NCT00130715 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Seprafilm Bioresorbable Membrane is the first listed.
NCT00130715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130715 about?
NCT00130715 is a clinical study titled "Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery". The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic absce...
What is the current status of trial NCT00130715?
This trial is currently completed. It is a NA study. The study started on 1998-06. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00130715?
The interventions under investigation include: Seprafilm Bioresorbable Membrane (DEVICE).
Who is sponsoring clinical trial NCT00130715?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.